PHIO

Phio Pharmaceuticals Corp

PHIO, USA

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

https://phiopharma.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PHIO
stock
PHIO

Phio Reports Positive Phase 1b PH-762 Skin Cancer Data TipRanks

Read more →
PHIO
stock
PHIO

Phio cancer drug clears tumors in 10 of 14, no dose-limiting toxicities Stock Titan

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$14

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

6.61

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-24.31 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-20.79 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.17

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 5.37% of the total shares of Phio Pharmaceuticals Corp

1.

Geode Capital Management, LLC

(1.0074%)

since

2025/06/30

2.

Macquarie Healthcare I

(0.8731%)

since

2025/07/31

3.

Vanguard Group Inc

(0.8498%)

since

2025/06/30

4.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6117%)

since

2025/07/31

5.

Cetera Investment Advisers

(0.5675%)

since

2025/06/30

6.

Fidelity Extended Market Index

(0.4861%)

since

2025/07/31

7.

Virtu Financial LLC

(0.2497%)

since

2025/06/30

8.

Fidelity Total Market Index

(0.2334%)

since

2025/07/31

9.

Spartan Extended Market Index Pool F

(0.1393%)

since

2025/07/31

10.

Morgan Stanley - Brokerage Accounts

(0.1048%)

since

2025/06/30

11.

Fidelity Series Total Market Index

(0.0996%)

since

2025/07/31

12.

Royal Bank of Canada

(0.0605%)

since

2025/06/30

13.

Spartan Total Market Index Pool G

(0.049%)

since

2025/07/31

14.

SBI Securities Co Ltd

(0.0333%)

since

2025/06/30

15.

DFA US Small Cap I

(0.0033%)

since

2025/07/31

16.

Genworth Financial Wealth Mgmt Inc

(0.0019%)

since

2025/06/30

17.

Bank of America Corp

(0.0008%)

since

2025/06/30

18.

NT Ext Equity Mkt Idx Fd - L

(0.0008%)

since

2025/06/30

19.

Northern Trust Extended Eq Market Idx

(0.0008%)

since

2025/06/30

20.

Mount Yale Investment Advisors, LLC

(0.0005%)

since

2025/06/30

21.

State St US Extended Mkt Indx NL Cl C

(0.0004%)

since

2025/08/31

22.

Activest Wealth Management

(0.0002%)

since

2025/06/30

23.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0002%)

since

2025/06/30

24.

SSgA U.S. Total Market Index Strategy

(0.0002%)

since

2025/03/31

25.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0002%)

since

2024/12/31

26.

Barclays PLC

(0.0001%)

since

2025/03/31

27.

Northern Trust Wilshire 5000

(0.0001%)

since

2025/06/30

28.

Blackstone Alternative Multi-Strategy I

(0.0001%)

since

2024/12/31

29.

Tower Research Capital LLC

(0%)

since

2025/06/30

30.

Citadel Advisors Llc

(0%)

since

2025/03/31

31.

UBS Group AG

(0%)

since

2025/06/30

32.

XTX Topco Ltd

(0%)

since

2025/06/30

33.

HRT FINANCIAL LLC

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.4374

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.